Hugo Sinha

Hugo Sinha

Auto-generated profile, based on publicly available information

Hugo Sinha

Department of Electrical and Computer Engineering, Concordia University, Montréal, Québec, Canada.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2017 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
PVPhilippe Q. N. Vo
Philippe Q. N. Vo
MHMathieu C. Husser
Mathieu C. Husser
FAFatemeh Ahmadi
Fatemeh Ahmadi
HSHugo Sinha
Hugo Sinha
SSSteve Shih
Steve Shih
A new feedback and biological analysis system for digital microfluidics that uses an imaging based setup.

10 July 2018 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
HSHugo Sinha
Hugo Sinha
AQAngela B. V. Quach
Angela B. V. Quach
PVPhilippe Q. N. Vo
Philippe Q. N. Vo
SSSteve Shih
Steve Shih
Gene-editing techniques such as RNA-guided endonuclease systems are becoming increasingly popular for phenotypic screening. Such screens are normally conducted in arrayed or pooled formats. There has been considerable interest in recent years to find new technological methods for conducting these gene-editing assays. We report here the first digital microfluidic method that can automate arrayed gene-editing in mammalian cells. Specifically, this method was useful in culturing lung cancer cells for up to six days, as well as implementing automated gene transfection and knockout procedures. In addition, a standardized imaging pipeline to analyse fluorescently labelled cells was also designed and implemented during these procedures. A gene editing assay for interrogating the MAPK/ERK pathway was performed to show the utility of our platform and to determine the effects of knocking out the RAF1 gene in lung cancer cells. In addition to gene knockout, we also treated the cells with an inhibitor, Sorafenib Tosylate, to determine the effects of enzymatic inhibition. The combination of enzymatic inhibition and guide targeting on device resulted in lower drug concentrations for achieving half-inhibitory effects (IC50) compared to cells treated only with the inhibitor, confirming that lung cancer cells are being successfully edited on the device. We propose that this system will be useful for other types of gene-editing assays and applications related to personalized medicine.